Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L Frandsen; Jonas Abrahamsson; Birgitte Lausen; Kim Vettenranta; Mats Heyman; Michael Behrentz; Anders Castor; Peder Skov Wehner; Britt-marie Frost; Louise Elisabeth Andersen; Kjeld Schmiegelow

doi:10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder Skov Wehner, Britt-marie Frost, Louise Elisabeth Andersen, Kjeld Schmiegelow

9 Citationer (Scopus)

Abstract

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

Originalsprog	Engelsk
Tidsskrift	British Journal of Haematology
Vol/bind	155
Udgave nummer	2
Sider (fra-til)	244-7
Antal sider	4
ISSN	0007-1048
DOI	https://doi.org/10.1111/j.1365-2141.2011.08835.x
Status	Udgivet - okt. 2011

Adgang til dokumentet

10.1111/j.1365-2141.2011.08835.x

Fingeraftryk

Dyk ned i forskningsemnerne om 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Frandsen, T. L., Abrahamsson, J., Lausen, B., Vettenranta, K., Heyman, M., Behrentz, M., Castor, A., Wehner, P. S., Frost, B., Andersen, L. E., & Schmiegelow, K. (2011). Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 155(2), 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. / Frandsen, Thomas L; Abrahamsson, Jonas; Lausen, Birgitte et al.

I: British Journal of Haematology, Bind 155, Nr. 2, 10.2011, s. 244-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Frandsen, TL, Abrahamsson, J, Lausen, B, Vettenranta, K, Heyman, M, Behrentz, M, Castor, A, Wehner, PS, Frost, B, Andersen, LE & Schmiegelow, K 2011, 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study', British Journal of Haematology, bind 155, nr. 2, s. 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M et al. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology. 2011 okt.;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x

Frandsen, Thomas L ; Abrahamsson, Jonas ; Lausen, Birgitte et al. / Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. I: British Journal of Haematology. 2011 ; Bind 155, Nr. 2. s. 244-7.

@article{d6b3c7d52eaf4b25a3ac9199619ac4b6,

title = "Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study",

abstract = "This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.",

author = "Frandsen, {Thomas L} and Jonas Abrahamsson and Birgitte Lausen and Kim Vettenranta and Mats Heyman and Michael Behrentz and Anders Castor and Wehner, {Peder Skov} and Britt-marie Frost and Andersen, {Louise Elisabeth} and Kjeld Schmiegelow",

note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",

year = "2011",

month = oct,

doi = "10.1111/j.1365-2141.2011.08835.x",

language = "English",

volume = "155",

pages = "244--7",

journal = "British Journal of Haematology, Supplement",

issn = "0963-1860",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

AU - Frandsen, Thomas L

AU - Abrahamsson, Jonas

AU - Lausen, Birgitte

AU - Vettenranta, Kim

AU - Heyman, Mats

AU - Behrentz, Michael

AU - Castor, Anders

AU - Wehner, Peder Skov

AU - Frost, Britt-marie

AU - Andersen, Louise Elisabeth

AU - Schmiegelow, Kjeld

PY - 2011/10

Y1 - 2011/10

N2 - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

AB - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

U2 - 10.1111/j.1365-2141.2011.08835.x

DO - 10.1111/j.1365-2141.2011.08835.x

M3 - Journal article

SN - 0963-1860

VL - 155

SP - 244

EP - 247

JO - British Journal of Haematology, Supplement

JF - British Journal of Haematology, Supplement

IS - 2

ER -